Cross-Stakeholder Initiative Standardizes Preliminary Confidentiality Practices Across Sponsors, CROs, and Sites COLUMBIA, Md., Oct. 1, 2025 /PRNewswire/ -- Advarra, the market...
Favorable End-of-Phase 2 meeting with U.S. FDA for FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA...
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of...
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate CommercializationFuture Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL...
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new...
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a...
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE...
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of...
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica...
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...
Appointments expand clinical and regulatory capabilities ahead of key program milestonesBOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc.,...
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for...
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead...